NurExone Biologic (FRA:J90) Change In Receivables : €-0.08 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Change In Receivables?

NurExone Biologic's change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means NurExone Biologic's Accounts Receivable declined by €0.00 Mil from Sep. 2024 to Dec. 2024 .

NurExone Biologic's change in receivables for the fiscal year that ended in Dec. 2024 was €-0.08 Mil. It means NurExone Biologic's Accounts Receivable increased by €0.08 Mil from Dec. 2023 to Dec. 2024 .

NurExone Biologic's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NurExone Biologic's liquidation value for the three months ended in Dec. 2024 was €0.02 Mil.

NurExone Biologic Change In Receivables Historical Data

The historical data trend for NurExone Biologic's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Change In Receivables Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-0.05

-0.01

-0.08

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial										-0.07	-0.17	-	0.09	-

NurExone Biologic Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08 Mil.

NurExone Biologic (FRA:J90) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NurExone Biologic's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, NurExone Biologic's accounts receivable are only considered to be worth 75% of book value:

NurExone Biologic's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.669	-	0.649	+	0.75 * 0	+	0.5 * 0
=	0.02

NurExone Biologic Change In Receivables Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NRXBF:USA NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines